Search - tctmd.com

Displaying 1 - 7 of 7

Sort: Relevancy | Date

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

News Conference News AHA 2018

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

November 10, 2018

VITAL: No Benefits to Vitamin D and Omega-3s in Reducing Major CV Events, Cancer

News Conference News AHA 2018

VITAL: No Benefits to Vitamin D and Omega-3s in Reducing Major CV Events, Cancer

November 10, 2018

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

News Daily News

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

Michael O'Riordan

November 07, 2018

OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients

News Conference News TCT 2018

OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients

September 24, 2018

GLOBAL LEADERS: Ticagrelor Monotherapy Fails to Beat Conventional DAPT After PCI

News Conference News ESC 2018

GLOBAL LEADERS: Ticagrelor Monotherapy Fails to Beat Conventional DAPT After PCI

Michael O'Riordan

August 27, 2018

Everyday Antiplatelet Decisions: Making the Right Choices

CME

Everyday Antiplatelet Decisions: Making the Right Choices

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.